HCW Biologics Inc (NASDAQ:HCWB) — Market Cap & Net Worth
Market Cap & Net Worth: HCW Biologics Inc (HCWB)
HCW Biologics Inc (NASDAQ:HCWB) has a market capitalization of $972.53K ($972.53K) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30220 globally and #5873 in its home market, demonstrating a 10.43% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HCW Biologics Inc's stock price $0.45 by its total outstanding shares 2151607 (2.15 Million). Analyse HCW Biologics Inc (HCWB) cash conversion ratio to see how efficiently the company converts income to cash.
HCW Biologics Inc Market Cap History: 2021 to 2026
HCW Biologics Inc's market capitalization history from 2021 to 2026. Data shows change from $4.99 Million to $972.53K (-42.35% CAGR).
Index Memberships
HCW Biologics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #906 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2871 of 3165 |
Weight: HCW Biologics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
HCW Biologics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HCW Biologics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.37x
HCW Biologics Inc's market cap is 0.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $4.99 Million | $4.10 Million | -$12.86 Million | 1.22x | N/A |
| 2022 | $4.12 Million | $6.72 Million | -$14.90 Million | 0.61x | N/A |
| 2023 | $2.64 Million | $2.84 Million | -$24.99 Million | 0.93x | N/A |
| 2024 | $959.83K | $2.57 Million | -$30.02 Million | 0.37x | N/A |
Competitor Companies of HCWB by Market Capitalization
Companies near HCW Biologics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to HCW Biologics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
HCW Biologics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, HCW Biologics Inc's market cap moved from $4.99 Million to $ 972.53K, with a yearly change of -42.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $972.53K | -53.43% |
| 2025 | $2.09 Million | +117.57% |
| 2024 | $959.83K | -63.58% |
| 2023 | $2.64 Million | -36.03% |
| 2022 | $4.12 Million | -17.46% |
| 2021 | $4.99 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of HCW Biologics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $972.53K USD |
| MoneyControl | $972.53K USD |
| MarketWatch | $972.53K USD |
| marketcap.company | $972.53K USD |
| Reuters | $972.53K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat p… Read more